MedTrace Logo

Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients

NCT02036554 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 234

Last updated 2014-09-25

No results posted yet for this study

Summary

To evaluate prevention effect of combination therapy of Everolimus and low-dose Tacrolimus in comparison with standard-dose Tacrolimus therapy with Mycophenolic acid on the New Onset Diabetes Mellitus after transplantation in the renal allograft recipients

Conditions

  • Kidney; Complications, Allograft

Interventions

DRUG

Everolimus

Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.

DRUG

Tacrolimus

Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.

DRUG

Mycophenolic acid

Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Seoul St. Mary's Hospital

    lead OTHER

Principal Investigators

  • Chul-Woo Yang, MD · St Mary's Hospital, London

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02036554 on ClinicalTrials.gov